《新股消息》健世科技-B(09877.HK)今起招股 每手入場費5,818.06元
內地醫療器械商健世科技-B(09877.HK)公布招股詳情,擬全球發售807.64萬股,香港公開發售佔近一成,國際配售佔近九成,每股招股價介乎26.7至28.8元。該股今日(23日)起招股,下周四(29日)中午截止,預期10月10日掛牌。每手200股,一手入場費5,818.06元。聯席保薦人為中金及花旗。
是次上市引入先健科技(01302.HK)作為基石投資者,認購公司2,000萬美元股份。
如以招股價中位數27.75元計,公司上市料淨集資約1.54億元,約65%將分配予核心產品(即LuX-Valve及KenValve)的研發、製造及商業化;約25%將分配予產品管線的其他在研產品(包括LuX-Valve Plus、KenFlex及二尖瓣產品)的研發、臨床試驗及產品註冊;約10%將用於營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.